Live Ipca Laboratories Share Price Chart

O 1330.6

H 1330.6

L 1330.6

VOL 289

Ipca Laboratories Performance

Days Range

Low: ₹1,324.10
High: ₹1,347.50
Previous Close ₹1,352.30
Open ₹1,330.60
Volume 2,12,457
Day’s Range ₹1,324.10 - ₹1,347.50
52W Range ₹669.80 - ₹1,374.60
Market Cap ₹34,313 Cr

Ipca Laboratories Fundamentals

ROCE (TTM) 10.82
P/E Ratio (TTM) 60.81
P/B Ratio 5.58
Industry P/E 36.11
Debt to Equity 0.32
ROE 8.01
EPS (TTM) 20.18
Dividend Yield 0.3
Book Value 242.36
Face Value 1

Ipca Laboratories Financials

Mar 2023Jun 2023Sep 2023Dec 2023
Net Sales1,511.631,585.212,033.962,052.86
Profit before tax129.44251.82225.36288.89
Operating Profit81.07166.21137.44222.65
Net Profit81.07166.21137.44222.65
EPS in Rs3.026.425.724.92

About Ipca Laboratories

Ipca Laboratories is involved in the manufacturing and marketing of pharmaceuticals. The company was incorporated as  `The Indian Pharmaceutical Combine Association Limited’ in 1949. The company has changed its name several times. At first, it changed its name to `Ipca Laboratories Ltd. in 1964. Two years later, in 1966, it changed its name to Ipca Laboratories Private Limited. In 1988, it again changed its name to Ipca Laboratories Ltd in 1988.

The company established a modern plant at Athal, Silvassa, for the manufacturing of pharmaceutical formulations in 1994. It launched a new domestic marketing division, ACTIVA, dedicated to Rheumatology Care in 2003. Ipca continued its inorganic growth in 2005 by acquiring the Cardiac brand ISORDIL from Wyeth Limited. In the same year, it finished its merger with Innotech Pharma Limited.

In 2008, Ipca Laboratories received US FDA approval for Propranolol Hydrochloride Tablets. Ipca Laboratories received approval from the UK Medicines and Healthcare Products Regulatory Agency for its 4th manufacturing unit at a Special Economic Zone in Indore for good manufacturing practices under the regulator in 2011.

The company finished the acquisition of a High Potency Oral Solid Dosage formulations manufacturing unit situated at Pithampur near Indore in 2014. It acquired a 100% stake in Ramdev Chemical Private Limited in 2019. In 2022, the company commenced a new green field manufacturing unit being set up at Dewas (Madhya Pradesh).

Business Segments

  • APIs: The company manufactures 80+ APIs at 12 production facilities, accounting for nearly 25% of its turnover. The company’s leadership extends across the manufacturing of Atenolol (anti-hypertensive) and Chloroquine Phosphate (anti-malarial).
  • Formulations: Under this segment, it manufactures 350+ formulations in almost every dosage form, with 4 of its branded formulations. It is a leader in Pain, Rheumatology, Antimalarials and Haircare therapies with a steadily growing portfolio. 
  • Global Business: The company has a rich presence across the UK, the USA and Russia. It operates its USA business through Bayshore Pharmaceuticals LLC.


As of 2022, the company had 11 subsidiaries and a few of them are listed below:

  • Ipca Laboratories (U.K.) Ltd: It is a wholly-owned subsidiary which was incorporated to apply for and obtain product registrations in the United Kingdom.
  • Ipca Pharmaceuticals, Inc. USA: It is a wholly-owned subsidiary that coordinates the development and registration of formulations developed by Ipcs in the USA as well as the distribution of Active Pharmaceutical Ingredients (APIs) manufactured in the US market.

Key Personnel

Ajit Kumar Jain, Managing Director & CFO

Mr A. K. Jain is a Chartered Accountant and a Science Graduate and has been with the company since 1981. He joined the company as a financial controller. He holds a rich experience of over 30, including 29 years in the pharmaceutical industry. Mr. Jain was first appointed to the Board as an Executive Director in 1994.

Corporate Actions

The company has no history of bonus issues, stock splits and other corporate actions.

Parent Organisation Indian Private
Founded 1949
Managing Director Premchand Godha

Peer Comparison

Stocks Market Cap (cr) Market Price (₹) 52 Week Low-High (₹)
Lupin Ltd ₹72,621.08


45.85 (-2.88%)

1541 - 1584View Peer Comparison
Gland Pharma Ltd ₹29,017.88


0.80 (-0.05%)

1736 - 1779.7View Peer Comparison
Syngene International Ltd ₹28,452.61


5.25 (0.74%)

696.5 - 720.8View Peer Comparison
Alkem Laboratories Ltd ₹55,582.78


34.50 (-0.74%)

4567.05 - 4644.95View Peer Comparison
Glaxosmithkline Pharmaceuticals Ltd ₹32,004.19


13.25 (-0.70%)

1854 - 1878.2View Peer Comparison

What's Trending

Ipca Laboratories FAQs

What is the Share price of Ipca Laboratories (IPCALAB)?

Ipca Laboratories (IPCALAB) share price as of April 19, 2024, on NSE is Rs 1,340.00 (NSE) and Rs 1,340.00 (BSE) on BSE.

Can I buy Ipca Laboratories (IPCALAB) shares?

Yes, You can buy Ipca Laboratories (IPCALAB) shares by opening a Demat account with Angel One.

How do I buy Ipca Laboratories (IPCALAB) from Angel One?

Ipca Laboratories (IPCALAB) share can be brought through the following modes:
  1. Direct investment: You can buy Ipca Laboratories (IPCALAB) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Ipca Laboratories (IPCALAB) shares.

Is IPCA Laboratories a Debt free Company?

No, IPCA Laboratories is not a debt free company.

What is the main business of IPCA Laboratories?

The main business of IPCA Laboratories is to produce and sell pharmaceutical products and drugs, including formulations, active pharmaceutical ingredients (APIs), and drug intermediates.

Who are the promoters of IPCA Laboratories?

Some of the promoters of IPCA Laboratories are Kaygee Investments Private Limited, Kaygee Laboratories Private Limited, Chandurkar Investments Private Limited, Paschim Chemicals Pvt Ltd, Premchand Godha, Usha M Chandurkar, Sameer M Chandurkar, Pranay Godh, Prashant Godha, and Usha Premchand Godha.

What are the Subsidiaries that comes under IPCA Laboratories?

Some of the subsidiaries that come under IPCA Laboratories include Ipca Pharmaceuticals, Inc., Ipca Laboratories (UK) Ltd., Ipca Pharma (Australia) Pty Ltd., Ipca Pharma Nigeria Ltd., Ipca Pharmaceuticals Ltd. SA de CV, Tonira Exports Ltd., and Ramdev Chemical Pvt. Ltd.